Turning hope into healthy brain aging
AUSPICA develops a patented nasal spray therapy and a blood test to prevent cognitive decline and slow brain aging, starting from Down syndrome.
Get in touchThe window to act is before symptoms appear
Down syndrome is a model of accelerated aging and a genetically determined form of Alzheimer’s disease. People with Down syndrome now live much longer, and Alzheimer’s disease has become the main limit to a long, independent life. Brain damage accelerates around the age of 40, and today no therapy exists to slow it down.
Two technologies that work together
A patented nasal spray therapy
A non-invasive nasal spray designed to deliver the active ingredient directly to the brain and counteract the early brain alterations seen in Down syndrome. First application: adults with Down syndrome, before dementia.
A blood test to know who to treat, and when
A simple blood test, in development, designed to identify who is at risk, who to treat and whether the treatment works, without invasive or costly examinations.
Both technologies are under development. They are not approved medical products and are not available for clinical use.
Where we stand
Next step. A pharmaceutical-grade nasal spray and the dossier to request the first clinical trial in Down syndrome.
Team
Eugenio Barone
Scientific lead and inventor. Full Professor of Biochemistry, Sapienza University of Rome.
Antonella Tramutola
Preclinical research and co-inventor. Associate Professor of Biochemistry, Sapienza University of Rome.
Flavia Cimini
Clinical translation. Physician, diabetologist.
Antonio Giampaolo
Entrepreneur and strategic advisor.